Intravitreal triamcinolone improves vision in Phase III study
24 September 2009
Katie McQue
Please Login to read the full article.
24 September 2009
Katie McQue
katie.mcque@informa.com
The anti-inflammatory corticosteroid triamcinolone improves vision and reduces vision loss associated with central retinal vein occlusion (CRVO), according to a Phase III study (SCORE-CRVO) sponsored by the US National Institutes of Health (NIH).
Until recently there were no available treatments...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE "yes" for Allergan's Ozurdex after comparison with off-label Avastin
- NICE no for Novartis' Lucentis is good news for Allergan's Ozurdex
- SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
- More Phase III success for Lucentis in DMO, but spectre of Avastin comparison awaits
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
